D Castillo-Martínez1, E Marroquín-Fabián2, A C Lozada-Navarro2, M Mora-Ramírez3, M Juárez2, F Sánchez-Muñoz3, J Vargas-Barrón4, J Sandoval4, L M Amezcua-Guerra5. 1. Department of Dermatology, Hospital General de Zona 32 Villa Coapa, Instituto Mexicano del Seguro Social, Mexico City, Mexico. 2. Department of Rheumatology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico. 3. Department of Immunology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico. 4. Division of Research, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico. 5. Department of Immunology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico Department of Health Care, Universidad Autónoma Metropolitana-Xochimilco, Mexico City, Mexico LaSalle University School of Medicine, Mexico City, Mexico lmamezcuag@gmail.com.
Abstract
OBJECTIVE: The objective of this paper is to assess whether pulmonary hypertension (PH) may be detected at one point in time or longitudinally predicted by serum uric acid (sUA) levels in systemic lupus erythematosus (SLE). METHODS: We conducted a post-hoc analysis of a long-term followed cohort of Mexican SLE patients. Echocardiography-based definitions of PH by the ESC/ERS/ISHLT and its associations with clinical and laboratory data on enrollment were studied. Especially, the impact that sUA levels at baseline may have on the future development of PH in patients with normal pulmonary artery systolic pressure (PASP) was explored. RESULTS: Out of the 156 SLE patients originally enrolled in the cohort, 44 met the inclusion criteria for the present study and were grouped as having (n =10) or not having (n = 34) PH. At baseline, sUA levels of 5.83 ± 1.79 and 5.82 ± 1.97 mg/dl (p = ns) were found in patients with and without PH, respectively. No association between PASP and other markers was found. In patients with normal PASP, the presence of sUA ≥ 7 mg/dl at baseline predicted future development of PH (relative risk 8.5, 1.0009 to 72; p = 0.04). CONCLUSION: In SLE, sUA levels at one point in time are useless to detect PH. However, steady hyperuricemia may predict the future development of PH in patients with normal PASP at baseline.
OBJECTIVE: The objective of this paper is to assess whether pulmonary hypertension (PH) may be detected at one point in time or longitudinally predicted by serum uric acid (sUA) levels in systemic lupus erythematosus (SLE). METHODS: We conducted a post-hoc analysis of a long-term followed cohort of Mexican SLEpatients. Echocardiography-based definitions of PH by the ESC/ERS/ISHLT and its associations with clinical and laboratory data on enrollment were studied. Especially, the impact that sUA levels at baseline may have on the future development of PH in patients with normal pulmonary artery systolic pressure (PASP) was explored. RESULTS: Out of the 156 SLEpatients originally enrolled in the cohort, 44 met the inclusion criteria for the present study and were grouped as having (n =10) or not having (n = 34) PH. At baseline, sUA levels of 5.83 ± 1.79 and 5.82 ± 1.97 mg/dl (p = ns) were found in patients with and without PH, respectively. No association between PASP and other markers was found. In patients with normal PASP, the presence of sUA ≥ 7 mg/dl at baseline predicted future development of PH (relative risk 8.5, 1.0009 to 72; p = 0.04). CONCLUSION: In SLE, sUA levels at one point in time are useless to detect PH. However, steady hyperuricemia may predict the future development of PH in patients with normal PASP at baseline.
Authors: C Reátegui-Sokolova; Manuel F Ugarte-Gil; Rocío V Gamboa-Cárdenas; Francisco Zevallos; Jorge M Cucho-Venegas; José L Alfaro-Lozano; Mariela Medina; Zoila Rodriguez-Bellido; Cesar A Pastor-Asurza; Graciela S Alarcón; Risto A Perich-Campos Journal: Clin Rheumatol Date: 2017-01-18 Impact factor: 2.980
Authors: N P Nickel; J M O'Leary; E L Brittain; J P Fessel; R T Zamanian; J D West; E D Austin Journal: Pulm Circ Date: 2017-03-13 Impact factor: 3.017
Authors: Claudia Elera-Fitzcarrald; Cristina Reátegui-Sokolova; Rocio Violeta Gamboa-Cardenas; Mariela Medina; Francisco Zevallos; Victor Román Pimentel-Quiroz; Jorge Mariano Cucho-Venegas; José Alfaro-Lozano; Zoila Rodriguez-Bellido; Cesar Augusto Pastor-Asurza; Risto Alfredo Perich-Campos; Graciela S Alarcón; Manuel Francisco Ugarte-Gil Journal: Lupus Sci Med Date: 2020-02-05